Results 11 to 20 of about 32,667 (266)

AI-derived and Manually corrected segmentations for various IDC Collections [PDF]

, 2023
The Imaging Data Commons (IDC)(https://imaging.datacommons.cancer.gov/) [1] connects researchers with publicly available cancer imaging data, often linked with other types of cancer data.
Van Oss, Jeff, Murugesan, Gowtham Krishnan, Soni, Rahul, McCrumb, Diana   +3 more
core   +3 more sources

IDC Herzliya

InDret, 2020
Pablo Salvador Coderch
doaj   +1 more source

Commentaries on IDC Theory in practice

Research and Practice in Technology Enhanced Learning, 2022
A total of seven scholars were invited to provide commentaries to the paper on the IDC experimental school in Taiwan. We collated their commentaries below, arranged in alphabetical order of the authors’ last names. We acknowledge and appreciate the excellent points raised by the commentators regarding the current and future ...
Wenli Chen 0004, Kampei Hayashi, Mas Nida Md. Khambari, Kinshuk, Jon Mason, Lung-Hsiang Wong, Kui Xie   +6 more
openaire   +1 more source

Hack your organizational innovation: literature review and integrative model for running hackathons

Journal of Innovation and Entrepreneurship, 2023
This article aims to offer a comprehensive overview of the existing literature on the hackathon phenomenon to offer scholars a common ground for future research and managers and practitioners research-based guidelines on best planning and running a ...
Ben Heller, Atar Amir, Roy Waxman, Yossi Maaravi   +3 more
doaj   +1 more source

Does Existence of Ductal Carcinoma In Situ Accompanying Invasive Ductal Carcinoma Lead to Different Clinicopathological Features and Clinical Outcome? Report of a Breast Cancer Registry [PDF]

Middle East Journal of Cancer, 2022
Background: Ductal carcinoma in situ (DCIS) is widely recognized as the precursor of invasive ductal carcinoma (IDC). We aimed to compare clinicopathological characteristics and prognosis between IDC with and without coexisting DCIS stratified by ...
Sedigheh Tahmasebi, Baharak Shahin, Masoumeh Ghoddusi Johari, Majid Akrami, Vahid Zanguri, Abdolrasoul Talei, Zahra Keumarsi, Nazanin Karimaghaei   +7 more
doaj   +1 more source

The Socio-Economic Impact of Corporate Social Responsibility Practices in Sri Lankan Tea Manufacturing Companies (Special Reference to Kandy District)

Kelaniya Journal of Management, 2014
Corporate Social Responsibility (CSR) is very important topic in the present competitive business environment. The aim of this exploratory study is to capture the current status of Corporate Social Responsibility (CSR) awareness, commitment and practices
IDC Wijerathna, Ridmi Gajanayaka
doaj   +1 more source

Overexpression of TPL2 may be a predictor of good prognosis in patients with breast invasive ductal carcinoma

Scientific Reports, 2023
The objective of this study was to investigate the clinical significance and roles of tumor progression locus 2 (TPL2) and peptidyl-prolyl cis–trans isomerase 1 (Pin1) in the occurrence and development of breast invasive ductal carcinoma (IDC ...
Qin Yu, Dan Wan, Rong Fu, Feng Li, Yutao Zhang   +4 more
doaj   +1 more source

Evaluación de la respuesta patológica al tratamiento neoadyuvante en cáncer de recto. Experiencia del Instituto de Cancerología de Medellín (Colombia, 2011-2017)

Revista de Gastroenterología de México, 2021
Resumen: Introducción y objetivos: La terapia neoadyuvante en el cáncer de recto se asocia con una disminución del tamaño tumoral y es la indicación terapéutica para pacientes con tumores T3, T4 o con compromiso ganglionar.
L.J. Palacios-Fuenmayor, A.M. Naranjo-Isaza, C.A. Serna-Ortiz, D.A. Mosquera-Castro, L.M. Arbeláez-Leon, L.R. Gómez-Wolff, H.I. García-García, L.A. Sánchez-Patiño   +7 more
doaj   +1 more source

Evaluation of the pathologic response to neoadjuvant treatment in rectal cancer. Experience at the Instituto de Cancerología de Medellín (Colombia, 2011-2017)

Revista de Gastroenterología de México (English Edition), 2021
Introduction and aims: Neoadjuvant therapy in rectal cancer is associated with a decrease in tumor size and is the therapeutic indication for patients with T3 or T4 tumors or lymph node involvement.
L.J. Palacios-Fuenmayor, A.M. Naranjo-Isaza, C.A. Serna-Ortiz, D.A. Mosquera-Castro, L.M. Arbeláez-Leon, L.R. Gómez-Wolff, H.I. García-García, L.A. Sánchez-Patiño   +7 more
doaj   +1 more source

SARS-CoV-2 Spike Antibody Levels Trend among Sinopharm Vaccinated People

Iranian Journal of Public Health, 2021
None
Umar Saeed, Sara Rizwan Uppal, Zahra Zahid Piracha, Rizwan Uppal   +3 more
doaj   +1 more source